Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

P331

Allopurinol and azathioprine co-therapy or thioguanine dose splitting: shifting the shunters in the mercaptopurine pathway in a paediatric inflammatory bowel disease population—a single-centre experience

Authors:

S. Chadokufa*1, A. Lozinsky Rolnik2, S. Sider1, N. Acton3, B. Huggett3, N. Shah4, F. Kiparissi1

1Great Ormond Street Hospital, Gastro, London, United Kingdom, 2Great Ormond Street Hospital, Gastro, LONDON, United Kingdom, 3Great Ormond Street, London, United Kingdom, 4Great Ormond Street, Gastro, London, United Kingdom

P332

Influence of mesalamine maintenance therapy on progression of ulcerative proctitis in Korea

Authors:

Y. S. Choi1, W. J. Kim*2, H.-J. Jung3, J. K. Kim1, K.-H. Song3

1Daehang Hospital, Gastroenterology, Seoul, South Korea, 2Soonchunhyang University Hospital, Gastroenterology, Gumi-si, South Korea, 3Daehang Hospital, Surgery, Seoul, South Korea

P333

Long-term efficacy and safety of thiopurines in patients with steroid-dependent ulcerative colitis: a retrospective investigation

Authors:

Y. Yokoyama*, T. Sato, M. Kawai, Y. Kita, K. Kamikozuru, T. Miyazaki, M. Iimuro, N. Hida, S. Nakamura

Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine, Nishinomiya, Japan

P334

Evolution of a long-term follow-up cohort of Crohn’s disease with complex perianal fistula: from antibiotic to combined AZA and anti-TNF based treatment ending up clinical and radiological healing with or without stoma

Authors:

Y. Erzin*, K. Ercaliskan, I. Hatemi, K. Atay, S. Bozcan, N. Demir, A. F. Celik

Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey

P335

Cancer recurrence with immunosuppressive therapy in immune-mediated diseases: a systematic review and meta-analysis

Authors:

E. Shelton*1, D. Laharie2, F. Scott3, R. Mamtani4, J. Lewis4, J.-F. Colombel5, A. Ananthakrishnan1

1Massachusetts General Hospital, Boston, Massachusetts, United States, 2University-Bordeaux, Bordeaux, France, 3University of Pennsylvania, Philadelphia, Pennsylvania, United States, 4University of Pennsylvania Perelman School of Medicine, Division of Gastroenterology, Philadelphia, Pennsylvania, United States, 5Mount Sinai, Icahn School of Medicine, New York, New York, United States

P336

French prospective, longitudinal observational study of the therapeutic management of mild to moderate ulcerative colitis (Optimum study): follow-up at 3 years

Authors:

S. Nahon*1, G. Bonnaud2, F. Bahbah3

1Centre Hospitalier Le Raincy, Montfermeil, France, 2Ambroise Paré Private hospital, IBD Unit, Toulouse, France, 3Ferring Pharmaceuticals, Gentilly, France

P337

Anti-TNFalpha therapy is associated with rapid reduction of circulating monocyte numbers and blunted monocyte pro-inflammatory response in patients with Crohn’s disease

Authors:

S. Slevin*1, C. Dennedy2, A. Ribeiro1, R. Ceredig1, M. Griffin1, L. Egan2

1National University of Ireland Galway, REMEDI, Galway, Ireland, 2National University of Ireland Galway, Pharmacology and Therapeutics, Galway, Ireland

P338

Rate and predictors of mucosal healing in patients with ulcerative colitis treated with thiopurines: results of a multicentric cohort study

Authors:

C. Prieux-Klotz*1, S. Nahon2, A. Amiot3, L. Sinayoko4, C. Galéano-Cassaz5, S. Chaussade1, P. Lahmek6, V. Abitbol1

1C.H.U. Cochin, Paris, France, 2C.H. Le Raincy Montfermeil, Montfermeil, France, 3C.H.U. Henri Mondor, Créteil, France, 4H.I.A. Bégin, Saint Mandé, France, 5H.I.A. Val de Grâce, Paris, France, 6C.H. Emile Roux, Limeil-Brévannes, France

P339

The efficacy of intravenous iron therapy in IBD patients with active disease is not influenced by the degree of inflammatory activity

Authors:

A. Walper*1, A. Dignass2, 3, J. Stein3, 4

1Medice Arzneimittel GmbH, Iserlohn, Germany, 2Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany, 3Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 4DGD Clinics Sachsenhausen, Frankfurt/Main, Germany

P340

Postoperative clinical recurrence in Crohn’s disease patients: the Practicrohn study

Authors:

E. Domènech*1, V. García2, M. D. Martín Arranz3, M. Barreiro-de Acosta4, A. Gutiérrez5, L. Cea-Calvo6, C. Romero6, B. Juliá6

1Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, 2Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain, 3Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, 4Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 5Hospital General Universitario Alicante, Gastroenterology Unit, Alicante, Spain, 6MSD Spain, Medical Department, Madrid, Spain

P341

Analytical performance of a new iPhone-based patient monitoring system comparable to ELISA for measuring faecal calprotectin in inflammatory bowel disease patients

Authors:

K. F. Wintgens*1, A. A. Wulandari2, A. Dignass3, 4, F. Hartmann3, 4, J. Stein2, 3

1Immundiagnostik AG, Bensheim, Germany, 2DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 3Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 4Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany

P342

Tryptophan as a biomarker for the course of IBD and anti-TNF α response

Authors:

B. Brandt*1, S. Nikolaus2, N. Al-Massad2, J. Bethge2, D. Schuldt2, S. Szymczak3, F. Thieme4, G. H. Waetzig5, M. Krawczak3, R. Junker4, P. Rosenstiel6, S. Schreiber2

1UKSH Kiel, Department of Internal Medicine I, Kiel, Germany, 2UKSH, Department of Internal Medicine I, Kiel, Germany, 3UKSH, Institute of Medical Informatics and Statistics, Kiel, Germany, 4UKSH, Institute of Clinical Chemistry, Kiel, Germany, 5Conaris Research Institute AG, Kiel, Germany, 6UKSH, Institute of Clinical Molecular Biology, Kiel, Germany

P343

The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease and the relationship with biochemical markers of disease activity

Authors:

K. Diederen1, D. Hoekman*1, T. Hummel2, T. de Meij3, B. Koot1, M. Tabbers1, A. Vlieger4, A. Kindermann1, M. Benninga1

1Academic Medical Centre (AMC), Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 2Medisch Spectrum Twente, Department of Paediatrics, Enschede, Netherlands, 3VU University Medical Centre, Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 4St. Antonius Hospital, Department of Paediatrics, Nieuwegein, Netherlands

P344

Non-adherence to medical therapy is associated with hospitalisations and the development of active disease in inflammatory bowel disease

Authors:

M. Severs*1, H. H. Fidder1, M.-J. Mangen2, M. E. van der Valk1, M. van der Have1, A. A. van Bodegraven3, 4, C. H. M. Clemens5, G. Dijkstra6, J. M. Jansen7, D. J. de Jong8, N. Mahmmod9, P. C. van de Meeberg10, A. E. van der Meulen- de Jong11, M. Pierik12, C. Y. Ponsioen13, M. J. L. Romberg- Camps3, P. D. Siersema1, J. R. Vermeijden14, J. van der Woude15, P. N. Zuithoff16, B. Oldenburg1

1University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands, 2University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, Netherlands, 3ORBIS medical Centre, Gastroenterology and Hepatology, Sittard, Netherlands, 4VU medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 5Diaconessenhuis, Gastroenterology and Hepatology, Leiden, Netherlands, 6University Medical Centre Groningen, Gastroenterology and Hepatology, Groningen, Netherlands, 7Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, 8University Medical Centre St. Radboud, Gastroenterology and Hepatology, Nijmegen, Netherlands, 9Antonius Hospital, Gastroenterology and Hepatology, Nieuwegein, Netherlands, 10Slingeland Hospital, Gastroenterology and Hepatology, Doetinchem, Netherlands, 11Leiden University Medical Centre, Gastroenterology and Hepatology, Leiden, Netherlands, 12University Medical Centre Maastricht, Gastroenterology and Hepatology, Maastricht, Netherlands, 13Academic Medical Centre Amsterdam, Gastroenterology and Hepatology, Amsterdam, Netherlands, 14Meander Medical Centre, Gastroenterology and Hepatology, Amersfoort, Netherlands, 15Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, Netherlands, 16University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, Netherlands

P345

The Great Continental Divide: use of anti-TNF therapy in paediatric inflammatory bowel disease is significantly different in North America compared with other parts of the world.

Authors:

P. Church1, J. Hyams2, F. Ruemmele3, L. de Ridder4, D. Turner5, A. Griffiths*1, o.b.o. the International Paediatric IBD Network (PIBDNet)6

1Hospital for Sick Children, University of Toronto, Department of Gastroenterology, Hepatology and Nutrition, Toronto, Canada, 2Connecticut Children’s Medical Centre, Hartford, United States, 3Hospital Necker Enfants Malades, Department of Paediatric Gastroenterology, Paris, France, 4Children’s Hospital Erasmus MC Sophia, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 5Shaare Zedek Medical Centre, Department of Paediatric Gastroenterology, Jerusalem, Israel, 6International Paediatric IBD Network (PIBDNet), Paris, France

P346

Soluble transferrin receptor and its relation to anaemia in inflammatory bowel disease

Authors:

R. Dudkowiak*, K. Neubauer, E. Poniewierka

Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland

P347

Identification of a cut-off for persistent anti-infliximab antibodies as a predictor of response to infliximab monotherapy

Authors:

L. Del Nero*1, G. Bodini2, E. Giannini2, J. Anjali3, V. Savarino1, E. Savarino4

1University of Genoa, Internal Medicine Department, Genoa, Italy, 2University of Genoa, Department of Gastroenterology and Internal Medicine, Genoa, Italy, 3Prometheus Laboratories, Department of Research and Development, San Diego, California, United States, 4University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Padua, Italy

P348

Novel model of care: the effect of a combined inflammatory bowel disease and antenatal clinic

Authors:

C. Selinger*1, N. Carey1, G. Ulivi2, L. Walker2, F. Shaik1, T. Glanville2

1St James University Hospital, Gastroenterology, Leeds, United Kingdom, 2St James University Hospital, Obstetrics, Leeds, United Kingdom

P349

The effects of smoking on thiopurine metabolism

Authors:

B. Warner*1, E. Johnston1, S. Fong1, P. Blaker1, M. Arenas-Hernandez2, A. Marinaki2, J. Sanderson1

1Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2Guy’s and St Thomas’ NHS Foundation Trust, Purine Laboratory, Viapath, London, United Kingdom

P350

The use of concomitant immunomodulators with adalimumab therapy in paediatric Crohn’s disease

Authors:

K. Benkov*1, G. Russell2, C. Samson3, S. Steiner4, E.C. King5, J. Pratt5, S. Eichner6, R.B. Colletti7, ImproveCareNow Network8

1Icahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology, New York, New York, United States, 2Boston Children’s Hospital, Harvard School of Medicine, Boston, Massachusetts, United States, 3Washington University School of Medicine, Saint Louis, Missouri, United States, 4Riley Hospital for Children, Pediatric Gastroenterology, Hepatology and Nutrition, Indianapolis, Indiana, United States, 5Cincinnati Children’s Hospital Medical Centre, Division of Biostatistics and Epidemiology, Cincinnati, Ohio, United States, 6AbbVie, Chicago, Illinois, United States, 7University of Vermont Children’s Hospital, Burlington, Vermont, United States, 8ImproveCareNow, Burlington, Vermont, United States